•Entering the era of disease modification in Crohn's disease
•Leucine-rich alpha-2 glycoprotein as a predictor of primary non-response to anti-TNF-alpha therapy in biologic-naive Egyptian IBD patients
•The exposome and inflammatory bowel disease: a framework for primary and primordial prevention
•Vedolizumab trough concentrations and clinical and endoscopic outcomes in inflammatory bowel disease: a systematic review and meta-analysis
•sFgl2‑enriched MSC-EVs attenuate colitis by enhancing immunoregulatory capacity
